DNDi awarded the Innovation Prize 2017 in Geneva for working to help the most neglected

From left to right: Juan Carlos Torres, President, CCIG, Fréderique Reeb-Landry, Director General, CCIG, Bernard Pécoul, Executive Director, DNDi, Michel Balestra, President of the Jury
From left to right: Juan Carlos Torres, President, CCIG, Bernard Pécoul, Executive Director, DNDi, Fréderique Reeb-Landry, Director General, CCIG, Michel Balestra, President of the Jury

As part of the ‘Evénement économique 2017’ that took place on November 9, the Geneva Chamber of Commerce, Industry and Services (CCIG), the Department of Security and Economy (DSE) and the Office for the Promotion of Industries and Technologies (OPI) awarded the Innovation Prize 2017 to the Drugs for Neglected Diseases initiative (DNDi).
[Français]

The prize was awarded in recognition of DNDi’s innovative and collaborative model, as well as the progress DNDi has made in medical innovation for neglected patients. Since its creation in 2003, DNDi has already developed and implemented seven treatments against malaria, sleeping sickness, visceral leishmaniasis, Chagas disease, and paediatric HIV. DNDi’s portfolio also includes 16 new chemical entities, some of which could be future new medicines to treat neglected diseases and change the lives of patients and healthcare workers.

Pierre Maudet, Conseiller d'État of Geneva Canton speaks to Bernard Pécoul, Executive Director of DNDi after watching a virtual reality film about sleeping sickness in DR Congo
Pierre Maudet, Conseiller d’État of Geneva Canton speaks to Bernard Pécoul, Executive Director of DNDi, after watching a virtual reality film about sleeping sickness in the Democratic Republic of Congo

We are very honoured to receive this Innovation Prize here in Geneva, where it all began for DNDi almost 15 years ago,” said Dr Bernard Pécoul, DNDi’s Executive Director. “Innovation is essential when the mission is to develop new treatments for patients who do not represent a profitable market. We had to be innovative to bring together public and private partners into our collaborative model. We will have to continue to be innovative to meet our objectives: developing oral, safe, and effective treatments that are affordable and adapted to field conditions, which are sometimes challenging, in countries where health systems remain fragile. Since innovation is not possible in isolation, we are happy to share this Prize with all of our partners and donors, in Switzerland and around the world”.  

 

To support DNDi’s work: www.dndi.org/donate or contact Caroline Gaere: cgaere@dndi.org

For media: media@dndi.org

 

 

Photo credits: G. Maillot/point-of-views.ch